Human type 3 parainfluenza viruses (PIV3) are important lower respiratory tract pathogens of infants and children (3) . The surface glycoproteins, the hemagglutinin-neuraminidase (HN) and fusion (F) proteins, mediate the attachment and penetration of viruses into host cells (14, 30) , and antibodies to these surface proteins probably play a key role in the development of immunity (23, 26, 32) . Children typically experience several PIV3 infections of decreasing severity before effective immunity is achieved (4) . It has been shown that antibodies to HN develop after primary infection, but a significant immune response to F and the acquisition of a measurable neutralizing antibody titer occur only after subsequent reinfection (18) . These observations suggest that antibodies to the F glycoprotein are important modulators of the severity of PIV3 infections in children.
The F glycoprotein not only mediates fusion of the virion envelope with host cell membranes during the initial stages of infection, but also is responsible for the fusion of infected cells with uninfected cells during later stages of replication (31) . Cell-to-cell fusion is a likely means of virus spread in vivo and results in vitro in the appearance of characteristic syncytia.
Although the antigenic and functional properties and the molecular epidemiology of the human PIV3 HN protein have been analyzed in detail (6, 7, 28, 29) , this type of information has not been available for the F protein. This has been due, in part, to the difficulty in generating neutralizing monoclonal antibodies (MAbs) to the F proteins of paramyxoviruses (27, 29) , even though monospecific polyclonal antibodies to the F protein are neutralizing (22) . The present report describes immunization protocols for producing both neutralizing and nonneutralizing F-specific MAbs to human PIV3. These MAbs were used to dissect the antigenic structure and functional organization of the F molecule and to evaluate the degree of antigenic variation in F proteins of PIV3 clinical strains. * Corresponding author.
MATERIALS AND METHODS
Cell and viruses. LLC-MK2 and BSC-1 cells were obtained from the American Type Culture Collection (Rockville, Md.) (CCL 7 and 26) and maintained in Eagle modified essential medium (EMEM) supplemented with 10% fetal bovine serum. Semiconfluent monolayers were infected with PIV3 in serum-free EMEM maintenance medium. Purified virions used for mouse immunizations or as enzyme-linked immunosorbent assay (ELISA) antigen were concentrated from infected LLC-MK2 cell culture medium and purified in 30 to 45% sucrose gradients (7) . Prototype PIV strains (PIV1/C39/ 57, PIV2/Greer/55, PIV3/Washington/47885/57, and PIV4b/ 19503/62) were obtained from American Type Culture Collection and propagated in LLC-MK2 cells. In the present study, unless otherwise stated, PIV3 refers to the prototype strain. Other PIV3 clinical isolates have been previously described (6) . Vaccinia (Table 2) . Several attempts to select variants resistant to MAbs c284, c199, b102, c145, and c128 were unsuccessful, possibly owing to the relatively low neutralizing titers of several of these antibodies (see Table 3 ). Analysis of the antigenic variants ( assigned by competitive binding ELISA (Fig. 1) . Epitope assignments were based on unique reactivity patterns of MAbs with clinical strains, except for MAbs c145 and b108, which were distinguished by their unique reactivities with laboratory-selected antigenic variants (Table 2) . Epitopes N1 to N14 are recognized by neutralizing MAbs. Percent variation indicates the percentage of clinical strains which are resistant to the indicated neutralizing MAb or do not react in ELISA with nonneutralizing MAbs.
Biological activities of PIV3 F MAbs. Since antibodies directed to epitopes located in different functional domains of the F molecule might be expected to display different biological activities, we tested the panel of MAbs in standard neutralization assays, FT assays and CEPTRA (Table 3) .
MAbs directed to epitopes in sites A, AB, B, and C (with the exception of MAb b48 in site A) all neutralized virus infectivity, indicating that these particular antigenic regions may correspond to functional domains of the F molecule. To determine whether these domains are regions involved in fusion activity, we tested the MAbs in standard Fl assays. These assays measure inhibition of fusion independently of virus neutralization; neutralizing anti-HN MAbs did not react in the FI assay (data not shown), and several anti-F MAbs with comparable neutralizing titers (for example, MAbs c267 and c214) had very different FT capacities. The results of the Fl tests indicated that whereas all of the MAbs directed to site AB, B, and C epitopes inhibited fusion, less than half of those binding to site A epitopes inhibited fusion. These data suggest that epitopes within sites AB, B, and C are more proximal to the fusion-active site than are most of the epitopes within site A. These data also suggest that anti-F antibodies can neutralize virus infectivity by a mechanism other than inhibition of fusion. DISCUSSION The development of a vaccine to control PIV3 disease requires an understanding of the functional, antigenic, and epidemiologic properties of the viral surface glycoproteins. We have previously defined the immunogenic and functional domains of the PIV3 HN protein and described antigenic variation within these domains (6), located amino acids involved in binding of neutralizing, hemagglutination-inhibiting, and neuraminidase-inhibiting MAbs (5, 8) , and documented a high degree of nucleotide and amino acid conservation in the HN genes of PIV3 clinical strains (7) . The present report defines the immunogenic, neutralization, and functional domains of the PIV3 fusion glycoprotein and provides a more complete picture of the epidemiology of human PIV3.
Each of the three immunization protocols used in the present study proved useful for generating F-specific MAbs which have neutralizing activity. The anti-F MAbs were highly specific for PIV3, showing little cross-reactivity with other types of human PIVs. These results were not unexpected, in light of the lack of cross-reactivity of PIV3 anti-HN MAbs (6) and of F-specific polyclonal antiserum (17) PIV3 and RSV F glycoproteins share features of functional organization and antigenic structure, which one would expect for fusion proteins of viruses within the same family. For PIV3, we showed that the neutralizing activity of MAbs directed to two antigenic sites and to the bridge site can be augmented by complement. Association of complement-enhanced neutralization with particular antigenic sites has also been shown for gp87 of bovine herpesviruses (24) . Although the mechanism responsible for this enhancement is currently unknown, our observations strengthen the argument that PIV3 F antigenic regions correspond to distinct functional domains.
In contrast to the antigenic stability of the F nonneutralization sites, there is a high degree of antigenic variation in two of the four F neutralization domains of clinical PIV3 strains. Seven neutralization epitopes in site A and all three of those in site B undergo antigenic variation. Variation in multiple F epitopes frequently occurs simultaneously, resulting in the cocirculation of antigenically very different strains (such as Texas/545/80 and Texas/535/81). These striking changes in F antigenicity could be due to differences in glycosylation (21) or may reflect the existence of more than one antigenic subtype of PIV3, analogous to the genetic dimorphism described for the RSV subgroup A and B glycoproteins. Sequence analysis of clinical strains as well as antigenic analysis with F MAbs produced to those strains are required to address this question. Whether PIV3 strains displaying dramatically different antigenic profiles have a different epidemiologic potential is unknown. However, it seems unlikely that variation in the F glycoprotein alone could significantly influence the ability of a particular strain to reinfect seropositive children, since the conservation of the HN neutralization epitopes would be expected to render these strains susceptible to neutralization.
In addition to the above-described changes in F epitopes which result in resistance to neutralization owing to failure of antibody binding, we also documented many instances in which certain PIV3 strains are refractory to neutralization even though the antibody binds quite efficiently. Identical results have been obtained with neutralizing MAbs to yellow fever virus, Sindbis virus, and rabies virus (2, 12, 34) . These observations, which indicate that antibody binding is necessary but not sufficient for virus neutralization, imply that the mechanism of virus neutralization does not simply involve steric hindrance of the interaction between a fusogenic region of the F protein and host cell membranes. A more complex mechanism of neutralization is required to explain why the binding of antibody to certain epitopes of some PIV3 strains does not cause the anticipated biological consequence (i.e., neutralization). A possible explanation is that specific amino acid substitutions in F epitopes of clinical strains do not abolish antibody binding (20) , but act to stabilize the conformation of regions of the F molecule which must be distorted to neutralize virus infectivity. Indeed, the complex pattern of nonreciprocal competitive binding among the neutralizing MAbs suggests that, in addition to the previously documented conformational changes in F induced by cleavage-activation (15), basic pH (16) , disulfide bonding (13) , and glycosylation (21), antibody binding also influences F conformation. Antigen distortion has been proposed to account for the one-or two-hit kinetics of influenza A virus neutralization (35) and has been directly demonstrated for influenza virus neuraminidase-antibody complexes (11) . We are currently sequencing the F genes of laboratory-selected antigenic variants and of clinical PIV3 strains (some of which do not bind neutralizing MAbs and some of which bind MAbs without neutralization) to identify amino acid substitutions which may be responsible for the different biological consequences of antibody binding.
